Cytoreductive nephrectomy in the era of immune‐checkpoint inhibitors: back to the future?

Our findings highlight reconsidering the importance of CN in the ICI era, potentially driven by the influence of tumour burden on anti-cancer immunity and the limited efficacy of ICIs against primary tumours. Future research, ideally through randomised trials involving patients suitable for safe surgery, should aim to clarify the optimal timing of CN in the context of ICI therapy.

Authors

Institutions

Publication Details

Journal
British Journal of Urology
Published
2026-02-11
DOI
https://doi.org/10.1111/bju.70168
Primary Topic
Renal cell carcinoma treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Cytoreductive nephrectomy in the era of immune‐checkpoint inhibitors: back to the future?

Fabio Calabrò, R. Campi, R. Bertolo, the Young Academic Urologists (YAU) Renal Cancer Working Group et al.
British Journal of Urology
Renal cell carcinoma treatment
article

Cytoreductive nephrectomy in the era of immune‐checkpoint inhibitors: back to the future?

Fabio Calabrò, R. Campi, R. Bertolo, the Young Academic Urologists (YAU) Renal Cancer Working Group, Giuseppe Simone, Rocco Simone Flammia, Costantino Leonardo, Eugenio Bologna, Daniele Amparore
article en

Abstract

Our findings highlight reconsidering the importance of CN in the ICI era, potentially driven by the influence of tumour burden on anti-cancer immunity and the limited efficacy of ICIs against primary tumours. Future research, ideally through randomised trials involving patients suitable for safe surgery, should aim to clarify the optimal timing of CN in the context of ICI therapy.

British Journal of Urology
European Association of Urology (NL), Azienda Ospedaliera Universitaria Integrata Verona (IT), Azienda Ospedaliero-Universitaria Careggi (IT), National Cancer Institute (MY), Candiolo Cancer Institute (IT), University of Florence (IT), University of Turin (IT), Sapienza University of Rome (IT)
Openalex Percentile: Top 60%
Renal cell carcinoma treatment
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.